171 related articles for article (PubMed ID: 7981903)
1. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status.
Doglioni C; Dei Tos AP; Laurino L; Chiarelli C; Barbareschi M; Viale G
Virchows Arch; 1994; 424(1):47-51. PubMed ID: 7981903
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
3. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
Soslow RA; Carlson DL; Horenstein MG; Osborne MP
Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors.
Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P
Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926
[TBL] [Abstract][Full Text] [Related]
5. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence.
Coradini D; Pellizzaro C; Veneroni S; Ventura L; Daidone MG
Br J Cancer; 2002 Nov; 87(10):1105-11. PubMed ID: 12402149
[TBL] [Abstract][Full Text] [Related]
6. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
8. Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas.
Frolik D; Caduff R; Varga Z
Histopathology; 2001 Nov; 39(5):503-13. PubMed ID: 11737309
[TBL] [Abstract][Full Text] [Related]
9. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.
Leek RD; Kaklamanis L; Pezzella F; Gatter KC; Harris AL
Br J Cancer; 1994 Jan; 69(1):135-9. PubMed ID: 8286195
[TBL] [Abstract][Full Text] [Related]
10. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables.
Binder C; Marx D; Overhoff R; Binder L; Schauer A; Hiddemann W
Ann Oncol; 1995 Dec; 6(10):1005-10. PubMed ID: 8750153
[TBL] [Abstract][Full Text] [Related]
12. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy.
Gee JM; Robertson JF; Ellis IO; Willsher P; McClelland RA; Hoyle HB; Kyme SR; Finlay P; Blamey RW; Nicholson RI
Int J Cancer; 1994 Dec; 59(5):619-28. PubMed ID: 7960234
[TBL] [Abstract][Full Text] [Related]
13. bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining.
Nakopoulou L; Michalopoulou A; Giannopoulou I; Tzonou A; Keramopoulos A; Lazaris AC; Davaris PS
Histopathology; 1999 Apr; 34(4):310-9. PubMed ID: 10231398
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
[TBL] [Abstract][Full Text] [Related]
15. Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas.
Luna-Moré S; de los Santos F; Bretón JJ; Cañadas MA
Pathol Res Pract; 1996 Jan; 192(1):27-32. PubMed ID: 8685038
[TBL] [Abstract][Full Text] [Related]
16. Biological profile of in situ breast cancer investigated by immunohistochemical technique.
Albonico G; Querzoli P; Ferretti S; Rinaldi R; Nenci I
Cancer Detect Prev; 1998; 22(4):313-8. PubMed ID: 9674874
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity.
Bhargava V; Kell DL; van de Rijn M; Warnke RA
Am J Pathol; 1994 Sep; 145(3):535-40. PubMed ID: 8080038
[TBL] [Abstract][Full Text] [Related]
18. bcl-2 expression in the spectrum of preinvasive breast lesions.
Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
[TBL] [Abstract][Full Text] [Related]
19. Expression of c-erbB3 protein in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty MK
Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
[TBL] [Abstract][Full Text] [Related]
20. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
Moran MS; Yang Q; Haffty BG
Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
